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Abstract
Due to high cervical cancer rates and limited research on human papillomavirus (HPV) vaccine 
acceptability in India, the research team examined parental attitudes towards HPV vaccines. 
Thirty-six interviews with parents were conducted to assess STI-related knowledge and HPV-
specific vaccine awareness and acceptability. Despite limited knowledge, parents had positive 
views toward HPV vaccines. Common barriers included: concerns about side effects, vaccine cost, 
and missing work to receive vaccine. Parents were strongly influenced by healthcare providers’ 
recommendations. Our findings suggest that addressing parental concerns, health worker training 
and polices, and efforts to minimize cost will be central to successful HPV vaccine 
implementation.
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Cervical cancer is the most common cancer among Indian women, closely followed by 
breast cancer. In 2008, age-standardized incidence and mortality rate estimates cervical 
cancer in India were 27.0 and 15.2 per 100,000 women respectively, which is considerably 
higher compared to the global estimates (15.2 and 7.8 per 100,000 women) (Ferlay et al., 
2008) [Globocan, 2008]. Nearly 60% of high-grade lesions and 80% of cervical cancers are 
due to HPV-16 and HPV-18. Organized cervical cancer screening programs have 
significantly reduced cervical cancer rates in developed countries. Although the National 
Cancer Program in India supports early screening and treatment of cervical cancer, 
implementations of screening programs are inadequate or non-existent due to logistical 
barriers such as insufficiently trained staff and infrastructure (Das et al., 2009).
Vaccinating against human papillomavirus (HPV) infection, therefore, is a promising 
additional strategy for reducing cervical cancer rates. Vaccination may be especially 
relevant in India, home to one-fifth of the worldwide cervical cancer burden, which 
represents the largest burden in the world (Jemal et al., 2011; Sankaranarayanan, Budukh, & 
Rajkumar, 2001) and where screening programs are inadequate (Dabash, et al., 2005). In 
2008, the Indian Academy of Pediatrics Committee of Immunization, along with the 
Federation of Obstetric and Gynaecological Societies of India, and the WHO Strategic 
Advisory Group of Experts on Immunization, recommended HPV vaccine for 10–12 year 
old females, with catch up vaccination through age 26 (IAPCO, 2008). The public health 
sector supports a childhood immunization program, which provides the Expanded Program 
on Immunization (EPI) in India for free, but other vaccines, like HPV vaccines, are solely 
available for purchase through the private sector. Compared to younger children, adolescents 
are traditionally underserved by India’s healthcare system (Kumar, Prinja, & Lakshmi, 
2008; Nath & Garf, 2008). In addition to parents (Bharadwaj, Hussain, Nasarem, &B Das, 
2009; Das, Hussain, Nasarem, & Bharadwaj, 2008), community perceptions, political will, 
provider support, and innovative delivery strategies will be important for acceptance and 
sustainability of HPV vaccination and adding the vaccine into the EPI schedule in India.
The context for HPV vaccination has been described in the developed (Brewer & Fazekas, 
2007; Zimet et al., 2006; Zimet et al., 2008) and developing (specifically Asia) world (Basu 
& Mittal, 2011; Bingham, Drake, & Lamontagne, 2009; Dinh, et al., 2007; Jacob, et al., 
2010; Kwan, et al, 2008; Madhivan, et al., 2010; Sam, et al., 2009). A review of these 
studies indicates that government endorsement, cancer prevention, confidence in 
immunizations, and provider’s recommendation are factors in vaccine acceptance. Major 
obstacles to acceptance are high cost and fear of side effects. There have been a few studies 
targeting parents in India (Basu & Mittal, 2011; Bingham, et al., 2009; Jacob, et al., 2010; 
Madhivanan, et al, 2010), these researchers suggest a relatively positive response to 
vaccinating 9–15 year olds.
Understanding HPV vaccine acceptability India is crucial given the enormous cultural, 
religious, and ethnic diversity and that relatively little research has been done in India (for 
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exceptions see (Basu & Mittal, 2011; Bingham, et al., 2009; Jacob, et al., 2010; Madhivan, 
et al., 2010)) compared to the extensive research done in England, Australia, and the United 
States (all much smaller countries with lower cervical cancer burden) (Brewer & Fazekas, 
2007; Zimet, Liddon, Rosenthal, Lazcano-Ponce, & Allen, 2006; Zimet, Shew, & Kahn, 
2008). Since social practices in India not only differ from other countries, but also 
significantly differ across states and geographical regions, the purpose of this study was to 
use qualitative research methods to examine parental, particularly mothers’, attitudes about 
HPV vaccine prior to its availability in peri-rural area outside of Hyderabad, India.
Methods
Study design and population
Parents were recruited in 2008 from Medchal Mandal and Shamirpet Mandal, Andhra 
Pradesh, India. The local private hospital is involved in community-based activities, 
including a population-based cervical cancer screening study, the Community Access to 
Cervical Health (CATCH) Study (Gravitt, et al., 2010). Villages in Medchal were selected 
based on their CATCH Study participation rates. Villages screening more than 45% of the 
population were considered high participation; villages screening under 45% were 
considered low. Three villages from both categories were purposively selected. In 
Shamirpet, with no active cervical cancer prevention activities, three villages were randomly 
selected. The Institutional Review Boards in India (SHARE India/MediCiti Institute of 
Medical Sciences) and the United States (Johns Hopkins Bloomberg School of Public 
Health) approved the protocol.
A list of eligible mothers (with daughter(s) under 18 years old) in Medchal was generated 
using the hospital’s computerized census database. Interviewers went to the house of every 
10th person on the list and invited the mother (or father) to participate until topical 
saturation was reached. In Shamirpet, a convenience sample of 2–4 eligible parents were 
selected from each village. Thirty-six interviews were completed, including 20 mothers from 
Medchal (10 high participation, 10 low participation) and 10 from Shamirpet; 6 fathers were 
interviewed from Medchal Mandal. Participation was voluntary and no incentive was 
provided.
Data Collection
After slight modifications for cultural appropriateness, a semi-structured interview guide 
from a U.S. study (Mays, Zimet, Winston, Kee, Dickes, & Su, 2000; Mays, Sturm, & Zimet, 
2004) was used. The guide was translated into the local language of Telugu and back 
translated into English. The interviews were conducted in Telugu; informed consent was 
obtained orally from all participants.
Individual interviews explored the socio-cultural environment and current vaccine 
infrastructure in Andhra Pradesh, India with respect to: (1) current vaccine utilization (e.g., 
Have your children received vaccines through the EPI program? What vaccines have they 
received?), (2) potential barriers to receiving existing and new vaccine (e.g., What are 
reason for not getting vaccines?), and (3) knowledge of HPV and related diseases (e.g., 
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What do you know about HPV? What are the potential outcomes related to HPV?), and (4) 
attitudes toward HPV immunization (e.g., Do you think an HPV vaccine is needed? At what 
age would you be willing to vaccinate your child for HPV?). Participants were asked about 
the current immunization programs and vaccine availability. Next, participants’ knowledge 
regarding HPV infection, genital warts, and cervical cancer was assessed. Since pilot testing 
of guide indicated very limited knowledge about HPV and HPV related diseases, a script 
was developed to provide medically accurate information on HPV, HPV vaccine and 
cervical cancer so participants could provide their opinions on HPV vaccines. The 
interviewer verbally provided this information to every participant before eliciting opinions 
about HPV vaccination. Demographic information (e.g., age, occupation, education, 
religion) were collected.
Data analysis
The interviews were audio-recorded, transcribed verbatim, and translated from Telugu into 
English. Prior to the analysis, all personal identifiers were removed. Qualitative data were 
managed using Atlas ti. 6.0 (Muhr, 2004). To analyze the interview data, a coding matrix 
was created based on the literature, interview questions, and preliminary readings of 
transcripts. Following constant comparison methodology, this coding structure was applied 
to the full transcripts and then transcripts were searched for negative cases to identify 
exceptions to the initial themes; codes were modified as needed, with returns to the data for 
additional comparisons across parents (e.g., by gender) (Glaser & Strauss, 1967). Emergent 
categories included: (1) STI, HPV & cervical cancer knowledge; (2) General vaccine 
knowledge & behaviors, and (3) HPV vaccine preferences & acceptability. The researchers 
selected quotes that best represented the themes illustrating the commonalities and 
individual variation among the parents and were edited for readability and clarity.
Results
Demographics
The participants were 19–62 years old (average = 30) and the majority were mothers (83%) 
and Hindu (81%). Education ranged from none to postgraduate degrees and most (67%) 
were employed. Table 1 provides a complete description of relevant demographic 
information.
Knowledge about STI, HPV, & cervical cancer
Parents had low levels of STI awareness with the exception of HIV/AIDS. Nearly all the 
respondents (n=28) reported HIV/AIDS knowledge with a high level of accurate 
information: “This infection affects people through multiple sexual contacts with unknown 
persons and also through injections” (mother, 35 years old). Conversely, seven participants 
reported not knowing about condoms (‘nirodh’).
In contrast to high HIV/AIDS knowledge, only two parents reported any knowledge of 
HPV. All but seven participants had heard of cervical cancer; however, only one knew 
cervical cancer was associated with an STI: “Sometimes, some HPV types cause warts in the 
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genital area called venereal or genital warts. It gets both in men and women. Sometimes, 
other HPV types cause cervical cancer.” (mother, 28).
General vaccine knowledge & behavior
Overall, parents understood that vaccinations were important “to have good health, to keep 
children healthy, and prevent disease” (mother, 20), with several parents (n=7) specifically 
stating that vaccines protect children’s health. One mother (28) added:
For the small children, vaccines are very much needed because, as we are educated, 
we know the importance of vaccines. It is important to give vaccine to children 
because we’ve seen children who suffered from polio. To avoid getting polio and 
other diseases, we give these vaccines, to better their childhood and then the child 
will be healthy and safe.
Despite the awareness of vaccine benefits, understanding was low about specific illnesses 
that vaccines target. While the majority of parents (n=35) reported their children received 
complete vaccinations, they were less sure about what their children had been vaccinated 
against. Some mentioned diseases such as polio and hepatitis, other parents were uncertain: 
“I don’t know the names, but my children they got vaccinated” (mother, 38). Several parents 
were unaware of need for vaccines to be given at older ages: “I don’t know, nobody told me 
[about need to vaccinate at 5 and 10 years of age]” (mother, 30). Not surprisingly, given that 
the vaccine was not currently available, none of the participants knew about the HPV 
vaccine.
Most parents reported having access to the government supported childhood immunization 
program. The program includes a government health worker or auxiliary nurse-midwife 
(ANM also called “government sister”) traveling monthly to the villages to provide a variety 
of vaccinations to infants. All program vaccines are provided free of charge, however, some 
parents paid for specific vaccines (e.g., at private clinics or vaccines not included in the 
government program). There were some noted differences between private and government 
vaccine locations, as illustrated by a parent who said that “In private settings there is no 
guarantee, we have belief in government…if any problem comes also we have chance to ask 
them” (mother, 24).
Extensive vaccine programs resulted in vaccine behavior being heavily influenced by health 
professionals. Several parents (n=8) reported a willingness to do whatever the doctor or 
health worker instructs them. “She [ANM] says if we give the vaccine from childhood 
onwards then we can prevent certain diseases, so that‘s why we’re prepared to give vaccines 
to children” (father, 38). Another father (35) commented that lack of education meant that 
they relied on the provided information:
We have not studied much and we don’t have much knowledge about these things 
even. The doctor gives our treatment; we only accept it. That’s all. We don’t know 
what types of medicine are given, the only thing we do is we follow according to 
what were suggested to us to do, that’s all.
Little emphasis was reported in helping parents understand the utility of the vaccines or the 
importance of booster vaccines for older children.
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HPV vaccine preferences & acceptability
Despite low levels of knowledge related to HPV and the associated vaccine, most parents 
were willing to vaccinate their children against HPV, especially with a health worker 
recommendation. Many parents (n=22) reported acceptance of girls-only vaccination. Others 
(n=12), however, indicated that the vaccine would only be acceptable if it was given to both 
girls and boys. The gendered behavioral expectations were highlighted by one mother (28):
Why? Mostly boys do wrong and we don’t know where he is going and what habits 
he has. Whereas girls’ parents, at least for a while, we will be back of her tracking 
what she is doing. So in my opinion if the vaccine is given to boys it will be good 
because he will also get this virus if he has bad behavior habits.
Conversely, one mother (28) discussed vaccination in terms of boys’ rights:
Parents will not accept, madam. Vaccine should be given to boys also…even they 
have the chance of getting this virus, right? First the virus will affect boys, right? 
So vaccine should be given to both boys and girls.
Preferences for HPV vaccine delivery included: injection (n=7), drops (n=5), tablets (n=4), 
or a combination (n=5). All parents reported they would vaccinate their children if the 
vaccines were free; 18 parents reported willingness to pay. Primary obstacles to vaccination 
were related to missing work for vaccine appointments and associated costs. Although 
vaccines were free (or low-cost) the family still lost daily wages, as noted by one mother 
(28):
When we say to them that they need to get children vaccinated, they say that they 
have work. And even sometimes, if the parents show interest, then the government 
sister will not come on time promptly to the village. The parents had to wait all day 
and lost work for that day and lost one day wages because of the government 
sister’s delay.
Overall, the most common barriers to HPV vaccination were work (n=12), cost (n=6), side 
effects (n=3), education (n=3), and other (e.g., effectiveness, karma; n=9). There was little 
concern related to transportation as most of the clinics were nearby or health workers came 
to the village.
Discussion
The purpose of the study was to assess parents’ attitudes about HPV vaccine as well as 
general vaccine and STI-related knowledge in a specific region of India. Our results 
indicated that among parents, STI- (with the exception of HIV/AIDS) and HPV-related 
knowledge were low yet HPV vaccine acceptability was high. Parents acknowledged the 
importance of vaccines for children’s health, which likely contributed to positive views of 
the HPV vaccine.
Similar to existing research (Basu & Mittal, 2011; Bingham, et al., 2009; Dinh, et al., 2007; 
Jacob, et al., 2010; Kwan, et al, 2008; Madhivanan, et al., 2010; Sam, et al., 2009), parents 
had not heard about HPV and had limited knowledge about cervical cancer. Although the 
relationship of HPV knowledge to vaccine acceptability varies (reviewed in Brewer & 
Paul et al. Page 6
Health Care Women Int. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fazekas, 2007 & Trim, Nagji, Elit, & Roy, 2012), communities continue accepting vaccines 
with insufficient knowledge. This practice suggests that parental knowledge may not be 
essential for successful programs (Nichter, 1995), however, public health ethics highlights 
need for better informed consent procedures. In contrast to results from another study 
(Krupp, et al., 2010), parents indicated that healthcare personnel’s recommendations and 
government endorsement play an integral role in vaccine behaviors (Basu & Mittal, 2011). 
Given the potential role of health providers and government officials, understanding their 
HPV vaccine attitudes should continued to be investigated.
Furthermore, there have been recent controversies in India over implementation of HPV 
vaccine studies (e.g., adverse event/side effects) resulting in the suspension of these projects 
(Choudhury & John, 2010; Larson, Brocard, & Garnett, 2010). Although the concerns were 
largely unfounded (Choudhury & John, 2010), these unfortunate events highlight the need 
for Indian health authorities and government officials to address people’s concerns clearly 
and quickly to dispel fears based on misinformation and focus on improving the informed 
consent process (Larson, et al., 2010).
Current immunization programs in Andhra Pradesh focus on children less than 2 years old. 
The majority of the households in our study reported their children received at least one of 
the EPI vaccines. This immunization coverage aligns with previous data; less than 5% of 
children in Andhra Pradesh had not received any vaccines at all by 2 years of age (NFHS, 
2009). Boosters for five and ten year olds are administered opportunistically at the primary 
health center, which may have implications for the addition of HPV vaccines to the 
expanded immunization program, given the later age of administration (9–26 years). While 
parental HPV vaccine acceptability was high, a primary challenge will be vaccinating 
adolescents who have less formal interactions with the healthcare system compared to 
existing vaccine for younger children.
The majority of parents reported acceptance of girls-only vaccination, however, some 
believed vaccines should be given to girls and boys. The interest in HPV vaccine for both 
genders is in line with the recent FDA approval of vaccination for males in the United States 
and needs to be explored further in Indian contexts as it has important implications for 
reducing HPV and cervical cancer rates.
Our data highlight parental concerns about vaccine-related side effects (Basu & Mittal, 
2011). The most common side effects for HPV vaccines are pain at the injection site (local) 
and headaches (systemic) (FDA, 2009). Although these side effects are not serious adverse 
events, they may represent concerns for the parents, be the basis for misinformation, and 
lead to negative HPV vaccine attitudes. It is important that personnel provide accurate 
information about safety and side effects to address potential concerns.
Several other issues were discussed as barriers to HPV vaccine acceptance, including cost, 
missing work and fitting into the existing program (Das, et al., 2008; Madhivanan, et al., 
2010; Jacob, et al., 2010; Sankaranarayanan, 2009; Zimet, et al., 2006; Zimet et al., 2008). 
While parents expressed apprehension about a vaccine requiring payment, they were also 
concerned about lost daily wages when taking their children to receive immunizations. This 
Paul et al. Page 7
Health Care Women Int. Author manuscript; available in PMC 2015 July 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
may be a contributing factor for high dropout rates between the first and third doses for 
vaccines like DPT and polio (Gupta, Gupta, Gupta, Venkatesh, & Lal, 2006) and may be an 
issue for a multi-dose HPV vaccine. This is an important consideration when designing 
vaccine programs. Transportation was not identified as a barrier to HPV vaccine acceptance 
because health workers come to the villages. While this is how childhood immunizations are 
delivered, it might not be feasible to reach adolescents through the community-based 
program. If the vaccine is not directly provided in the villages, then transportation may 
become a barrier. The feasibility of incorporating HPV vaccines into immunization 
programs needs to be explored further.
Although the introduction of the HPV vaccine is expected to reduce cervical cancer rates; 
there continues to be a debate in India about whether prevention resources should 
concentrate on vaccine-based primary prevention or cervical cancer screening programs. 
Even in the presence of a strong health infrastructure and an inexpensive test, low 
compliance with screening continues to be a barrier (Gravitt, et al., 2010; Dinshaw, et al., 
2007; Nene, et al., 1996). Screening is still essential in cervical cancer prevention as the 
population impact of a vaccine-based program will not be apparent for at least 15–20 years 
and the vaccine is not completely protective against cervical cancer (Basu & Chowdhury, 
2009). Women fear cancer diagnosis and frequently neglect their own health to take care of 
the family (Basu et al., 2006; Gravitt, et al., 2010). Therefore, mobilizing mothers to 
vaccinate their daughters to protect against cancer may be more effective. A multi-pronged 
approach with comprehensive education messages that promote HPV vaccination for 
adolescents and increase awareness of cervical cancer screening may be the most efficient 
use of resources, especially in low resource settings.
Individual interviews helped delineate personal beliefs about vaccination, but the small 
sample size and demographics of the participants (e.g., majority Hindu compared to 
Muslim) may not represent the whole community’s views. Potential religious differences 
and fathers’ influences on vaccine acceptance should be explored more fully. The 
relationship of HPV vaccine acceptability to actual vaccine uptake and coverage may by 
depend on a variety of factors such as mandatory vaccinations and vaccine delivery. HPV 
vaccine acceptance after programs are implemented needs to be evaluated.
Current HPV vaccine acceptability research has primarily been conducted in the United 
States, Europe and some Asian countries (Bingham, et al., 2009; Brewer & Fazekas, 2007; 
Dinh, et al., 2007; Kwan, et al, 2008; Zimet, et al., 2006; Zimet et al., 2008). Given the 
cervical cancer burden and the population density and diversity in India (and other 
developing countries), it is essential to get a better understanding of HPV vaccine 
acceptability. Programs that build on the strong infrastructure of the existing immunization 
program address parental concerns about vaccine safety and side effects, incorporate 
positive recommendation from health workers, governmental policy support, and have 
efforts to minimize cost of HPV vaccine are essential for the successful implementation and 
uptake of the HPV vaccine in India. The vaccine delivery mode, number of doses, and other 
logistical concerns may affect HPV vaccine acceptance and utilization. Although extensive 
educational campaigns may not be extremely helpful, ethically, accurate information about 
HPV vaccines and cervical cancer should be provided. Such education programs may allow 
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for development of a dialogue around the benefits of early protection from cervical cancer, 
thereby enhancing multi-pronged cervical cancer prevention.
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Table 1
Participant demographics
N %
Age (in years)
<25 9 25.0
25–34 14 38.9
25–44 9 25.0
45+ 2 5.6
DK/Not reported 2 5.6
Gender
Female 30 83.3
Male 6 16.7
Religion
Hindu 29 80.6
Christian 5 13.9
Not reported 2 5.6
Education status
None 13 36.1
1–8 12 33.3
9+ 9 25.0
Missing 2 5.6
Occupation
Not employed 12 33.3
Employed 24 66.7
Total number of children
1 3 8.3
2 19 52.8
3 10 27.8
4+ 4 11.1
Age of eldest daughter (in years)
16+ 7 19.4
9–15 12 33.3
<9 13 36.1
Missing 4 11.1
Vaccinated status of EPI vaccines
Not vaccinated 4 11.1
Vaccinated 21 58.3
Don't know 11 30.6
All children vaccinated through EPI program
Yes 35 97.2
No 1 2.8
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